The size of the global carrier screening market was estimated in 2023 at USD 1,343.40 million, and it is anticipated to exhibit a CAGR of 12.4% from 2023 to 2033. By 2033, the market is expected to be worth USD 4,323.84 million.
The market is anticipated to grow as a result of increased funding from the public and private sectors in response to the rising demand for genetic tests. The use of affordable technologies for carrier screening is regarded as a crucial factor.
The global carrier screening market is becoming more impacted by the advent of novel tests for improved diagnosis and treatment. The frequency of genetic abnormalities and chronic diseases is rising, which is helping the industry expand.
| Attributes | Details |
|---|---|
| Carrier Screening Market CAGR (2023 to 2033) | 12.4% |
| Carrier Screening Market Size (2023) | USD 1,343.40 million |
| Carrier Screening Market Size (2033) | USD 4,323.84 million |
Explore FMI!
Book a free demo
A disease has a higher chance of being effectively treated or cured the earlier it is discovered. It might also be easy to cope with the sickness if it is treated at an early stage.
People can make important decisions about their support and health needs, as well as regarding legal and financial issues, in the early stages of a disease, which helps them plan. Disorders that are inherited include Tay-Sachs disease, sickle cell anemia, and cystic fibrosis.
For a couple with a genetic problem, carrier testing for these disorders can give information about the likelihood of producing a child. Pre-symptomatic/predictive testing refers to risk identification before the onset of symptoms. Many genetic diseases can be identified early on during pregnancy.
The carrier screening market is expanding as a result of consumer desire for reliable and secure carrier tests. The integration of carrier tests into routine clinical treatment benefits the industry commercially.
Particularly in affluent countries like England, France, the United States, Italy, Japan, and Germany, the average age of first-time mothers has been rising. The primary drivers of maternal age advancement are a stable financial situation, rising literacy rates, and social variables. This results in surging carrier screening market adoption trends.
Maternal age increases are directly correlated with the probability of catastrophic chromosomal abnormalities. The average maternal age is increasing, which is predicted to raise the incidence of chromosomal abnormalities and increase the demand for carrier screening.
The carrier screening market on a global scale was estimated in 2017 to be worth USD 0.91 billion and is anticipated to expand at a CAGR of 11.7% from 2017 to 2021. In 2021, the market was estimated to be worth another USD 1.41 billion. The market's estimated value in 2019 was USD 1.13 billion.
The carrier screening industry is expected to increase at a faster rate than average during the forecast period, due to reasons such as the growing emphasis on early illness identification and prevention, rising customized medicine acceptance, and rising use of regular testing for genetic abnormalities.
Due to the region's growing prevalence of neurological, hematological, and pulmonary problems, as well as the consequent increase in the demand for testing, North America held a sizable market share in 2021.
The population's ethical concerns about carrier screening and the strict laws governing the clearance of carrier screening tests are impeding carrier screening market expansion. The lack of consistency among laboratories, the administration of pre- and post-test follow-up, and provider misconceptions are further implementation challenges that are projected to impede market expansion.
The price of carrier testing is probably going to limit market expansion. Since there is no requirement to take the test, insurance firms are free to set the terms and conditions following their policies. As a result, out-of-pocket costs may increase by an additional USD 100 to USD 1,000.
| Attributes | Details |
|---|---|
| Expanded Carrier Screening - CAGR | 12.9% |
With a 12.9% CAGR between 2023 and 2033, the expanded carrier screening (ECS) market is predicted to grow at a significant rate and generate the most revenue. The ECS is a new type of carrier screening that screens for a wide range of genetic illnesses, regardless of ethnic background. To increase their carrier screening market share, companies in the industry are engaging in strategic efforts, such as product development.
The company's enhanced test gives customers the option to ask for single- or multi-gene repeat expansion assessments. Consequently, it is anticipated that the informative test is poised to increase the test's utilization and help with individualized medical management.
The demand for carrier screening is likely to increase as people become more aware of genetic illnesses.
Multiple test types are supported by the program, including carrier screening, NIPT, and hereditary cancer. The main tests in carrier screening include a panel for SMA/CF, a screening for fragile X, a panel for Ashkenazi Jews, and a comprehensive panel based on guidelines.
Over 1,300 genetic diseases with recessive inheritance harm babies. The American College of Obstetricians and Gynecologists advises making carrier screening mandatory for all expectant mothers. According to estimates, carrier screening should pay particular attention to Cystic Fibrosis (CF).
When both parents carry the gene for cystic fibrosis, there is a 25% risk that the child is also going to have the condition, while there is a 50% chance that the infant is poised to only be a carrier. Similarly, one of the common recessive illnesses is Spinal Muscular Atrophy (SMA). A non-functional copy of SMN1 was inherited from parents in around 98% of afflicted instances.
This results in the escalation of carrier screening market trends.
| Attributes | Details |
|---|---|
| DNA Sequencing Segment Share | 39.9% |
With a market share of 39.9%, the DNA sequencing market category ruled the overall carrier screening market.
The carrier screening tests are performed at several prenatal diagnostics clinics that use sequencing technologies.
Chromosome micro-array and next-generation sequencing technologies are two examples of how technology is advancing quickly in the market.
The full-exon gene sequencing method based on NGS can find high carriers, according to the National Tay-Sachs and Allied Diseases Association. In terms of Tay-Sachs carrier screening, genotyping is thought to be less sensitive than NGS technology.
| Attributes | Details |
|---|---|
| Laboratory Segment Share | 47.1% |
With 47.1% carrier screening market share throughout the forecast period, the laboratory segment dominated the global market. Market participants are developing investment proposals as a result of the rising demand for genetic testing.
Considered to be the principal suppliers of sequencing solutions to the labs are Oxford Nanopore, Illumina, and ThermoFisher. To incorporate carrier screening services, the end-users are engaging in vertical acquisitions and mergers.
The rising use of carrier screening services in-house by end users is predicted to significantly affect the market's estimated value.
| Attributes | Details |
|---|---|
| Market Share | 40.19% |
With a share of 40.19% between 2033 and 2033, the North American carrier screening market is anticipated to have a commanding position in the industry. Since this area has a sophisticated and effective healthcare system.
The presence of several important firms in the North American region provides a competitive edge for market expansion. The industry is predicted to grow because there is a significantly higher awareness of chromosomal problems and how to prevent them in the area.
Hematological and neurological problems are more prevalent in North America, which reinforces the need for screening testing.
Due to the improved infrastructure of healthcare facilities, thoughtfully crafted reimbursement policies, and improving growth of economic elements, Asia Pacific is predicted to experience a large increase in the carrier screening market. The market is poised to grow as non-profit groups in the area take more initiatives.
Future growth is anticipated to be rapid in the Asia Pacific. The market is being driven by key competitors' growing investments, particularly in China and India. It is believed that the growing senior population and increased awareness of genetic illnesses are poised to fuel the market.
To expand the carrier screening market globally, businesses and service providers are using tactics including technological development and discovery, vertical collaboration, building a strong product portfolio through startups, mergers and acquisitions, and regional expansion.
Recent Development:
Funding
| Date | March 2022 |
|---|---|
| Company | Billion to One |
| Details | With significant support from Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, Time BioVentures, and Libertus Capital, among others, Billion to One raised USD 125 million in Series C funding in March 2022. This round of funding was co-led by Adams Street Partners and existing investor Hummingbird Ventures. |
Launch
| Date | January 2022 |
|---|---|
| Company | Mitera |
| Details | Peaches& Me and 23 Pears, Mitera's at-home reproductive genetic testing tools, are available in all 50 states from January 2022, the company revealed. It conducts screenings for ailments like down syndrome. |
| Date | June 2019 |
|---|---|
| Company | QIAGEN |
| Details | QIAGEN announced to launch QIAseq, an enhanced carrier screening panel, in June 2019. By providing information on the targets and genes, it is used to identify more than 200 disorders. |
| Date | 2017 |
|---|---|
| Company | OPKO Health |
| Details | In 2017, the OPKO Health subsidiary GenPath Women's Health introduced the CalriTest, a non-invasive prenatal screening method. This tool is poised to make it easier to spot faulty chromosomes. |
| Date | 2018 |
|---|---|
| Company | Invitae Corporation |
| Details | Invitae Corporation introduced its comprehensive genetic screening tool in 2018. |
Partnership
| Date | April 2021 |
|---|---|
| Company | Illumina |
| Details | Based on the data from Illumina's comprehensive genomic profile test, TruSight Oncology, Kartos Therapeutics, Inc., and Illumina established a partnership in April 2021 to jointly develop a TP53 companion diagnostic (CDx). It is poised to increase the range of TruSight Oncology's services, to include hematopoietic cancers of illumination. |
| Date | January 2019 |
|---|---|
| Company | Fulgent |
| Details | To provide Columbia patients with on-site performed, expanded carrier screening, Fulgent and Precision Genomics Laboratory (PGL) partnered in January 2019. To produce an enhanced carrier screening test with many advantages over other currently available tests, this alliance is poised to make use of both sides' expertise in laboratory management, bioinformatics, clinical genetics, and next-generation sequencing. |
The market is estimated to secure a valuation of USD 1,343.40 million in 2023.
The global market size to reach USD 4,323.84 million by 2033.
The growth potential of the carrier screening market is 12.4% CAGR through 2033.
Increasing investments in new technologies may drive the market forward.
High incidence of chromosomal abnormalities is expected to create opportunity for market players.
Protein Diagnostics Market Share, Size and Forecast 2025 to 2035
CGRP Inhibitors Market Trends - Growth, Demand & Forecast 2025 to 2035
Indolent Systemic Mastocytosis treatment Market Insights: Size, Trends & Forecast 2025 to 2035
Intraoperative Fluorescence Imaging Market Report - Demand, Trends & Industry Forecast 2025 to 2035
Lung Cancer PCR Panel Market Trends, Growth, Demand & Forecast 2025 to 2035
Polymyxin Resistance Testing Market Trends – Innovations & Growth 2025 to 2035
Carrier Screening Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
